Skip to main content
Registrieren
Springerpflege
SUCHE
MENÜ 1 2 3 4
main-content
nach oben

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Zeitschrift für Gerontologie und Geriatrie 1/2018

05.01.2018 | CME

Management der Osteoporose nach Fragilitätsfrakturen

verfasst von: Univ.-Prof. Dr. med. univ. M. Gosch, U. Stumpf, C. Kammerlander, W. Böcker, H. J. Heppner, S. Wicklein

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Osteoporose ist eine systemische Knochenerkrankung, die durch verminderte Knochenfestigkeit zum erhöhten Frakturrisiko prädisponiert. Gerade bei alten Personen besteht ein hohes Frakturrisiko, häufig bereits als Folge eines inadäquaten Traumas. Verletzungen dieser Art werden als Fragilitätsfrakturen bezeichnet. Ihre rasche chirurgische Versorgung und die nachfolgende frühzeitige Mobilisierung sind zum Standard der Frakturbehandlung im Alter geworden. Die Therapie der zugrunde liegenden Osteoporose tritt häufig in den Hintergrund der Akutversorgung. Nur ein kleiner Anteil der Patienten ist vortherapiert; nur wenige Patienten erhalten nach erlittener osteoporotischer Fraktur eine umfassende osteologische Medikation, die die Progredienz der Osteoporose mindert und das Eintreten weiterer Frakturen reduziert („osteoporosis care gap“). Der vorliegende Beitrag gibt einen Überblick über die Therapiemöglichkeiten und beantwortet zahlreiche Fragestellungen aus dem klinischen Alltag.
Vorheriger Artikel Super-aging and social security for the most elderly in China
Nächster Artikel Journal Club
Literatur
1.
Nih Consensus Development Panel on Osteoporosis Prevention Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795 CrossRef
2.
Mikosch P (2012) Diagnosis of osteoporosis in geriatric patients – possibilities and limitations. Wien Med Wochenschr 162(5–6):99–109 CrossRefPubMed
3.
Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany – the BoneEVA Study. Osteoporos Int 18(1):77–84 CrossRefPubMed
4.
WHO (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva, S 59
5.
Bogoch ER, Elliot-Gibson V, Beaton DE, Jamal SA, Josse RG, Murray TM (2006) Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am 88(1):25–34 PubMed
6.
Hadji P, Klein S, Haussler B, Kless T, Linder R, Rowinski-Jablokow M et al (2013) The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther 51(11):868–872 CrossRefPubMed
7.
Gosch M, Druml T, Nicholas JA, Hoffmann-Weltin Y, Roth T, Zegg M et al (2015) Fragility non-hip fracture patients are at risk. Arch Orthop Trauma Surg 135(1):69–77 CrossRefPubMed
8.
Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2):4–9 CrossRef
9.
Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV et al (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155 CrossRefPubMed
10.
Johnell K, Fastbom J (2009) Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people. Arch Osteoporos 4(1–2):17–23 CrossRefPubMedPubMedCentral
11.
Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58(4):650–657 CrossRefPubMedPubMedCentral
12.
Hadji P, Klein S, Gothe H, Haussler B, Kless T, Schmidt T et al (2013) The epidemiology of osteoporosis – Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int 110(4):52–57 PubMedPubMedCentral
13.
14.
Gosch M, Kammerlander C, Roth T, Doshi HK, Gasser RW, Blauth M (2013) Surgeons save bones: an algorithm for orthopedic surgeons managing secondary fracture prevention. Arch Orthop Trauma Surg 133(8):1101–1108 CrossRefPubMed
15.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57 CrossRefPubMed
16.
Neuerburg C, Mittlmeier L, Schmidmaier R, Kammerlander C, Bocker W, Mutschler W et al (2017) Investigation and management of osteoporosis in aged trauma patients: a treatment algorithm adapted to the German guidelines for osteoporosis. J Orthop Surg Res 12(1):86 CrossRefPubMedPubMedCentral
17.
Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92(4):1415–1423 CrossRefPubMed
18.
Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD et al (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691 CrossRefPubMedPubMedCentral
19.
Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA et al (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367(1):40–49 CrossRefPubMed
20.
21.
22.
Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almas B, Jorde R (2012) The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass – a randomized controlled 1‑year trial. Osteoporos Int 23(1):201–211 CrossRefPubMed
23.
Khaw KT, Stewart AW, Waayer D, Lawes CMM, Toop L, Camargo CA Jr. et al (2017) Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. Lancet Diabetes Endocrinol 5(6):438–447 CrossRefPubMed
24.
Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R et al (2016) Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med 176(2):175–183 CrossRefPubMed
25.
Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D et al (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303(18):1815–1822 CrossRefPubMed
26.
Gorter EA, Hamdy NA, Appelman-Dijkstra NM, Schipper IB (2014) The role of vitamin D in human fracture healing: a systematic review of the literature. Bone 64:288–297 CrossRefPubMed
27.
Gorter EA, Krijnen P, Schipper IB (2017) Vitamin D status and adult fracture healing. J Clin Orthop Trauma 8(1):34–37 CrossRefPubMed
28.
Goldhahn J, Feron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R et al (2012) Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 90(5):343–353 CrossRefPubMed
29.
Larsson S, Fazzalari NL (2014) Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg 134(2):291–297 CrossRefPubMed
30.
Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD et al (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308–1313 CrossRefPubMedPubMedCentral
31.
Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17(11):1645–1652 CrossRefPubMed
32.
Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809 CrossRefPubMed
33.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765 CrossRefPubMed
34.
Adami S, Libanati C, Boonen S, Cummings SR, Ho PR, Wang A et al (2012) Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am 94(23):2113–2119 CrossRefPubMed
35.
Gosch M, Kammerlander C, Pils K, Lechleitner M, Benvenuti-Falger U, Roth T et al (2012) Osteoporotic treatment options in geriatric patients. Z Gerontol Geriatr 45(5):417–428 (quiz 429) CrossRefPubMed
36.
Shi Z, Zhou H, Pan B, Lu L, Liu J, Kang Y et al (2016) Effectiveness of Teriparatide on fracture healing: a systematic review and Meta-analysis. PLoS ONE 11(12):e168691 CrossRefPubMedPubMedCentral
37.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645 CrossRefPubMed
38.
39.
Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23(12):2769–2774 CrossRefPubMed
40.
Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353:i3365 CrossRefPubMedPubMedCentral
41.
Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY et al (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 26(12):2763–2771 CrossRefPubMedPubMedCentral
42.
Gosch M, Kammerlander C, Nicholas JA (2014) Treatment of osteoporosis in older adults. Panminerva Med 56(2):133–143 PubMed
43.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22(10):1479–1491 CrossRefPubMed
44.
Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S et al (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142(11):1243–1251 CrossRefPubMed
45.
46.
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23 CrossRefPubMed
47.
Toro G, Ojeda-Thies C, Calabro G, Toro G, Moretti A, Guerra GM et al (2016) Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskelet Disord 17:227 CrossRefPubMedPubMedCentral
48.
49.
Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr., McLellan A et al (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039–2046 CrossRefPubMed
50.
Dell RM, Greene D, Anderson D, Williams K (2009) Osteoporosis disease management: what every orthopaedic surgeon should know. J Bone Joint Surg Am 91(Suppl 6):79–86 CrossRefPubMed
51.
Niedhart C, Preising A, Eichhorn C (2013) Significant reduction of osteoporosis fracture-related hospitalisation rate due to intensified, multimodal treatment – results from the Integrated Health Care Network Osteoporosis North Rhine. Z Orthop Unfall 151(1):20–24 PubMed
52.
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412–420 CrossRefPubMed
53.
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543 CrossRefPubMed
54.
Metadaten
Titel
Management der Osteoporose nach Fragilitätsfrakturen
verfasst von
Univ.-Prof. Dr. med. univ. M. Gosch
U. Stumpf
C. Kammerlander
W. Böcker
H. J. Heppner
S. Wicklein
Publikationsdatum
05.01.2018
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 1/2018
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-017-1355-7

Weitere Artikel der Ausgabe 1/2018

Zeitschrift für Gerontologie und Geriatrie 1/2018 Zur Ausgabe

Original Contribution

Burden of multimorbidity and outcome in ambulatory geriatric hemodialysis patients

Themenschwerpunkt

OurPuppet – Pflegeunterstützung mit einer interaktiven Puppe für pflegende Angehörige

Themenschwerpunkt

Emotionale Roboter im Pflegekontext

Correction

Correction: Ziel- und patientenorientierte Versorgung mithilfe des Comprehensive Geriatric Assessment

Journal Club

Journal Club

Editorial

Technik für vulnerable ältere Menschen und ihre Angehörigen